Tesamorelin product description — Synthetic GHRH analog peptide
Research Peptide · GHRH Analog · FDA Approved (Limited)
Tesamorelin
A synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), modified for extended half-life. Stimulates the pituitary’s own GH release in a physiologic, pulsatile pattern. Purity >99% · Double lab tested.
Regulatory status & approval
FDA approved November 2010 for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. In March 2025, the FDA approved a new weekly-reconstitution formulation (Egrifta WR / F8), bioequivalent to the original. Not indicated for general weight loss.
Developer
Theratechnologies
Brand names
Egrifta SV · Egrifta WR
New formulation (2025)
Weekly reconstitution (F8)
Dosing
Once-daily subcutaneous
Mechanism of action — upstream pituitary stimulation
GHRH receptor
Pituitary stimulation
Binds GHRH receptors on somatotroph cells of the anterior pituitary, triggering endogenous growth hormone release in the body’s natural pulsatile rhythm — preserving negative-feedback control.
Pituitary stimulation
Binds GHRH receptors on somatotroph cells of the anterior pituitary, triggering endogenous growth hormone release in the body’s natural pulsatile rhythm — preserving negative-feedback control.
Growth hormone axis
GH-driven tissue effects
Elevated GH acts on adipose, muscle, and other tissues. Because tesamorelin acts upstream rather than supplying exogenous GH, it preserves the normal pulsatile pattern and regulatory feedback loop.
GH-driven tissue effects
Elevated GH acts on adipose, muscle, and other tissues. Because tesamorelin acts upstream rather than supplying exogenous GH, it preserves the normal pulsatile pattern and regulatory feedback loop.
IGF-1 production
Visceral fat reduction
GH stimulates IGF-1 synthesis in the liver. The predominant clinically observable effect is reduction of visceral adipose tissue — the basis for the approved HIV-lipodystrophy indication.
Visceral fat reduction
GH stimulates IGF-1 synthesis in the liver. The predominant clinically observable effect is reduction of visceral adipose tissue — the basis for the approved HIV-lipodystrophy indication.
Clinical trial evidence
Pivotal Phase 3 — HIV-associated lipodystrophy
Adults with HIV-associated abdominal fat accumulation. Demonstrated statistically significant reductions in visceral adipose tissue over 26 weeks, alongside modest improvements in triglycerides and other metabolic markers.
15–18% VAT reduction
vs. placebo · 26 weeks
Triglyceride improvement
vs. placebo · 26 weeks
Triglyceride improvement
Investigator research — NAFLD / MASLD
Exploratory investigator-initiated studies examining tesamorelin in non-alcoholic fatty liver disease. Produced early findings but has not led to an additional approved indication.
Exploratory · Not approved
Investigator research — Cognitive function
Research into cognitive effects in older adults. Produced exploratory findings; no additional indication approval to date.
Exploratory · Older adults
Adverse effects & safety
Most commonly reported adverse reactions: arthralgia (joint pain), injection-site reactions, pain in the extremities, peripheral edema, and myalgia.
Hypersensitivity signal: anti-tesamorelin IgG antibodies detected in ~85% of patients who developed hypersensitivity reactions, with cross-reactivity to endogenous GHRH in ~60% of antibody-positive patients. Contraindicated in disruption of the hypothalamic-pituitary axis, active malignancy, pregnancy, and hypersensitivity to the drug or excipients. Not recommended in children with open or closed bone growth plates. Long-term cardiovascular safety has not been fully characterized.




Reviews
There are no reviews yet.